Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine GLP 1s: The Second Serving Citrini Research Efficacy and safety of co administered once weekly cagrilintide 24 mg with once weekly semaglutide 24 mg in type 2 diabetes: a multicentre, randomised, double blind, active controlled, phase 2 trial The Lancet Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants Gabe 2024 Diabetes, Obesity and Metabolism Wiley Online Library Efficacy and safety of cagrilintide 2.4 mg in adults with overweight obesity: Data from REDEFINE 1